Video Experimental Relacionado
Updated: Jul 20, 2026
06:41
A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis
Published on: March 9, 2015
Evaluación de un nuevo agente antihipertensivo. El minoxidil es el Minoxidil
JAMA
|July 4, 1980
Resumen
El minoxidil, un vasodilatador oral, trata eficazmente la hipertensión severa cuando se combina con diuréticos y betabloqueantes. Los efectos secundarios comunes incluyen retención de líquidos e hipertricosis.
Área de la Ciencia:
- Farmacología Farmacología.
- Medicina Cardiovascular La medicina cardiovascular es una especialidad de la salud.
Sus antecedentes:
- El minoxidil es un vasodilatador eficaz por vía oral.
- Ha demostrado efectos potentes y de acción prolongada.
Objetivo del estudio:
- Para describir el uso de minoxidil en la hipertensión severa.
- Para describir las reacciones adversas comunes asociadas con el tratamiento con minoxidil.
Principales métodos:
- El minoxidil se administra por vía oral.
- Se utiliza junto con un diurético y un fármaco beta-bloqueante.
- Esta terapia de combinación se dirige a la hipertensión severa que no responde a los tratamientos convencionales.
Principales resultados:
- El minoxidil maneja eficazmente la hipertensión severa y resistente al tratamiento.
- Las reacciones adversas más frecuentes observadas son la retención de líquidos y hipertricosis.
Conclusiones:
- El minoxidil es una valiosa opción terapéutica para la hipertensión severa.
- Los médicos deben monitorear la retención de líquidos y la hipertricosis durante el tratamiento con minoxidil.
Videos de Conceptos Relacionados
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:23Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:25Mitral Regurgitation III: Medical Management
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...